With several treatments available to care for the most urgent and severe cases of COVID-19, researchers are now investigating whether a common anti-inflammatory drug, ciclesonide, could help speed recovery in mild cases and put a stop to disease progression and potential hospitalization. When inhaled, the medication is directed to the nose and airways, the areas of the body most affected by the COVID-19 virus. While the long-term effects of the virus are not fully understood, studies have found that any level of disease severity can result in persistent physical and psychological symptoms. Ciclesonide has been shown to prevent viral activity against SARS-CoV-2 in some lab-based studies, and researchers hypothesize that giving it to patients early in the course of the disease could prevent the virus from replicating further and causing an increased inflammatory response.
Ciclesonide was approved by the US Food and Drug Administration in January 2008 for use in humans to treat asthma, rhinitis, and other nasal and airway conditions. The CONTAIN study team selected ciclesonide as a possible treatment option because of its low rate of side effects and drug interactions, as well as evidence linking this particular steroid with antiviral effects.
Dr Sara Belga, a clinical assistant professor in the Division of Infectious Diseases at the University of British Columbia, is the principal investigator in the province of the CONTAIN study, headed by Dr Nicole Ezer from the McGill University Centre for Health Outcomes Research. The study is recruiting individuals living in Quebec, Ontario, or British Columbia. Adults 18 years and older can qualify to participate if they apply via the CONTAIN study’s online portal within 5 days of being diagnosed with COVID-19. Eligible participants must also be recovering at home with a mild fever, shortness of breath, and/or symptomatic cough. Visit www.contain-covid19.com for more information about the study and how to participate.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org